Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Alexander Birkmann"'
Publikováno v:
Journal of Innate Immunity, Pp 1-1 (2024)
Introduction: Inactivated parapoxvirus ovis (iPPVO) exerts strong immunomodulatory effects on innate immune cells, making it an attractive therapeutic candidate. However, little is known about the signaling pathways that are involved in iPPVO-induced
Externí odkaz:
https://doaj.org/article/a8ccef77f3aa477f940a86ef7879efe8
Autor:
Dirk Kropeit, Susanne Bonsmann, Oliver von Richter, David McCormick, Jörg Pausch, Melanie Sumner, Alexander Birkmann, Holger Zimmermann, Helga Rübsamen‐Schaeff
Publikováno v:
Clinical Pharmacology in Drug Development.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c5887c1fe383470f851d2912aa34596
https://doi.org/10.1002/cpdd.1241
https://doi.org/10.1002/cpdd.1241
Autor:
Alexander Birkmann
Publikováno v:
New Drug Development for Known and Emerging Viruses. :133-150
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c096f35346abddd074463e373fcbed91
https://doi.org/10.1002/9783527810697.ch5
https://doi.org/10.1002/9783527810697.ch5
Autor:
Alexander Birkmann, Susanne Bonsmann, Dirk Kropeit, Tamara Pfaff, Manickam Rangaraju, Melanie Sumner, Burkhard Timmler, Holger Zimmermann, Helmut Buschmann, Helga Ruebsamen-Schaeff
Publikováno v:
Journal of medicinal chemistry. 65(20)
When the nucleoside analogue acyclovir was introduced in the early 1980s, it presented a game-changing treatment modality for herpes simplex virus infections. Since then, work has been ongoing to improve the weaknesses that have now been identified:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b69be1720a16217550c44fc70babd502
https://pubmed.ncbi.nlm.nih.gov/36202389
https://pubmed.ncbi.nlm.nih.gov/36202389
Autor:
Andreas Urban, Katharina Stolle, Alexander Birkmann, Ralf Bartenschlager, Stefan Seitz, Angelica Corcuera, Stefan Hillmer, Ji-Young Lee
Publikováno v:
Antiviral Research
One of the most promising viral targets in current hepatitis B virus (HBV) drug development is the core protein due to its multiple roles in the viral life cycle. Here we investigated the differences in the mode of action and antiviral activity of re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::231604841430f6849bbb7c7b968e7c03
https://doi.org/10.1016/j.antiviral.2018.07.011
https://doi.org/10.1016/j.antiviral.2018.07.011
Autor:
Debra C. Quenelle, Thomas Goldner, Alexander Birkmann, Tamara Pfaff, Holger Zimmermann, Terri L. Rice, Mark N. Prichard, Deborah J. Collins, Susanne Bonsmann
Publikováno v:
Antiviral Research. 149:1-6
Pritelivir, a helicase-primase inhibitor, has excellent in vitro and in vivo activity against human herpes simplex virus (HSV). Mice lethally infected with HSV type 1 or 2, including acyclovir-resistant strains, were treated 72 h after infection for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10120bfa283164eed57cc592845c456c
https://doi.org/10.1016/j.antiviral.2017.11.002
https://doi.org/10.1016/j.antiviral.2017.11.002
Autor:
Holger Zimmermann, Alexander Birkmann
Publikováno v:
Current Opinion in Virology. 18:9-13
Herpes simplex virus (HSV) types 1 and 2 can cause infections with clinical manifestations ranging from benign and generally self-limiting blisters or sores as seen in labial and genital herpes through to severe and in rare cases even life-threatenin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58d3607af73dcae6b0f555f3b08350cd
https://doi.org/10.1016/j.coviro.2016.01.013
https://doi.org/10.1016/j.coviro.2016.01.013
Autor:
Holger Zimmermann, Alexander Birkmann
Publikováno v:
Clinical Pharmacology & Therapeutics. 102:30-32
The alpha-herpesviruses varicella zoster virus (VZV) and herpes simplex virus (HSV) share common features including lifelong persistence in sensory ganglia and the risk of recurrences. For both HSV and VZV, standard-of-care (SoC) is based on nucleosi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf1073faf4de68e2bc8daf83b62da984
https://doi.org/10.1002/cpt.647
https://doi.org/10.1002/cpt.647
Autor:
Tamara Pfaff, Schwab Wilfried, Claudiu T. Supuran, Alexander Birkmann, Fabrizio Carta, Holger Zimmermann, Helmut Buschmann, Alfonso Maresca
A series of congeners structurally related to pritelivir, N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide, a helicase-primase inhibitor for the treatment of herpes simplex virus infections, was prepared. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7556a1211b03f00b2455159becadcb18
http://hdl.handle.net/2158/1141163
http://hdl.handle.net/2158/1141163
Autor:
Hans Peter Stobernack, Stephen K. Tyring, Amalia Magaret, Helga Ruebsamen-Schaeff, Anna Wald, Burkhard Timmler, Lawrence Corey, Stacy Selke, Alexander Birkmann, Kenneth H. Fife, Meei Li Huang, Christine Johnston, Terri Warren, Holger Zimmermann
Publikováno v:
JAMA. 316(23)
Importance Current therapy of herpes infections relies on nucleoside analogues. Pritelivir is a well-tolerated novel herpes simplex virus (HSV) helicase-primase inhibitor that reduced genital shedding and lesions. Objective To compare the efficacy of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21c36d0727ce883c2f7b4551204d77fb
https://pubmed.ncbi.nlm.nih.gov/28125749
https://pubmed.ncbi.nlm.nih.gov/28125749